Effect of ASA dose doubling versus switching to clopidogrel on plasma inflammatory markers concentration in patients with type 2 diabetes and high platelet reactivity: the AVOCADO study.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cardiology Journal

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.5603/CJ.2013.0045PMID 24469880
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lancet

  2021cited by this paper
• Standards of Medical Care in Diabetes

  2014cited by this paper
• The effect of doubling the dose of acetylsalicylic acid (ASA) on platelet function parameters in patients with type 2 diabetes and platelet hyperreactivity during treatment with 75 mg of ASA: a subanalysis of the AVOCADO study.

  2013cited by this paper
• C‐reactive protein concentration predicts mortality in type 2 diabetes: the Diabetes Heart Study

  2012cited by this paper
• Interleukin-6 in the prediction of primary cardiovascular events in diabetes patients: results from the ESTHER study.

  2011cited by this paper
• Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease

  2011cited by this paper
• Genetic determinants of platelet reactivity during acetylsalicylic acid therapy in diabetic patients: evaluation of 27 polymorphisms within candidate genes

  2011cited by this paper
• OX40 Ligand Levels and High-Sensitivity C-Reactive Protein Levels in Blood from Local Coronary Plaque and the Femoral Artery in Patients with Acute Coronary Syndrome or Stable Angina

  2011cited by this paper
• Review article: Platelet abnormalities in diabetes mellitus

  2010cited by this paper
• Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus.

  2010cited by this paper
• From atherosclerosis to acute coronary syndromes: the role of soluble CD40 ligand.

  2010cited by this paper
• Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

  2010cited by this paper
• Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis

  2009cited by this paper
• Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials

  2009cited by this paper
• Methods for the measurement of platelet function.

  2009cited by this paper
• Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients

  2009cited by this paper
• Effects of aspirin on serum C‐reactive protein and interleukin‐6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo‐controlled crossover trial

  2008cited by this paper
• Letter by Klein Regarding Article, "Evaluation of Dose-Related Effects of Aspirin on Platelet Function: Results From the Aspirin-Induced Platelet Effect (ASPECT) Study"

  2008cited by this paper
• The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study.

  2008cited by this paper
• Prognostic Implication of the Pre-Procedural Level of Platelet Aggregation Inhibition to ADP in Patients on Clopidogrel Undergoing Percutaneous Coronary Intervention

  2007cited by this paper
• Measuring antiplatelet drug effects in the laboratory.

  2007cited by this paper
• Clopidogrel resistance.

  2007cited by this paper
• Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin

  2007cited by this paper
• Soluble CD40L Versus Myocyte Enhancer Factor: Predicting a Prominent Marker For Cardiovascular Disease

  2006cited by this paper
• Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease.

  2006cited by this paper
• Soluble CD40L versus myocyte enhancer factor: predicting a prominent marker for cardiovascular disease.

  2006cited by this paper
• The potential role of antiplatelet agents in modulating inflammatory markers in atherothrombosis

  2006cited by this paper
• Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease.

  2006cited by this paper
• Soluble CD40L Versus Myocyte Enhancer Factor: Predicting a Prominent Marker For Cardiovascular Disease

  2006cited by this paper
• Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome--the Chennai Urban Rural Epidemiology Study.

  2006cited by this paper
• Level of high-sensitivity C-reactive protein is predictive of 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention.

  2005cited by this paper
• Influence of aspirin on inflammatory markers in patients after acute myocardial infarction.

  2003cited by this paper
• Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease

  2003cited by this paper
• Platelet abnormalities in diabetes mellitus

  2003cited by this paper
• Clinical implications of increased expression of CD40L in patients with acute coronary syndromes.

  2002cited by this paper
• Diabetes and atherosclerosis: epidemiology, pathophysiology, and management.

  2002cited by this paper
• Soluble P-Selectin and the Risk of Future Cardiovascular Events

  2001cited by this paper
• Soluble CD40L and Cardiovascular Risk in Women

  2001cited by this paper
• Significance of chemokines and activated platelets in patients with diabetes

  2000cited by this paper
• The New England Journal

  2000cited by this paper
• Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin.

  1999cited by this paper
• Platelet Abnormalities in Diabetes Mellitus

  1992cited by this paper

• MiR-126 Is an Independent Predictor of Long-Term All-Cause Mortality in Patients with Type 2 Diabetes Mellitus

  2021cites this paper
• [The CD40-CD40L axis: Current and future implications in clinical immunology].

  2021cites this paper
• Inflammatory state does not affect the antiplatelet efficacy of potent P2Y12 inhibitors in ACS

  2020cites this paper
• High serum sCD40L during the first week of malignant middle cerebral artery infarction and mortality.

  2019cites this paper
• The Utility of Anti-Inflammatory Agents in Cardiovascular Disease

  2018cites this paper
• The Potential Role of Platelet-Related microRNAs in the Development of Cardiovascular Events in High-Risk Populations, Including Diabetic Patients: A Review

  2018cites this paper
• Serum Brain-Derived Neurotrophic Factor is Related to Platelet Reactivity and Metformin Treatment in Adult Patients With Type 2 Diabetes Mellitus.

  2018cites this paper
• Serum Brain-Derived Neurotrophic Factor is Related to Platelet Reactivity but not to Genetic Polymorphisms within BDNF Encoding Gene in Patients with Type 2 Diabetes

  2016influential citation
• New single-nucleotide polymorphisms associated with differences in platelet reactivity and their influence on survival in patients with type 2 diabetes treated with acetylsalicylic acid: an observational study

  2016cites this paper
• Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.

  2016cites this paper
• Parathyroid hormone levels and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with acetylsalicylic acid and clopidogrel or ticagrelor

  2016cites this paper
• Effects of P2Y12 receptor antagonists beyond platelet inhibition – comparison of ticagrelor with thienopyridines

  2016cites this paper
• Soluble CD 40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization

  2015cites this paper
• A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk

  2015cites this paper
• Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization

  2015cites this paper
• The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study

  2015cites this paper
• ASS könnte in der kardiovaskulären Primärprävention nützlich sein

  2015cites this paper
• Anti-inflammatory therapy in the treatment of cardiovascular diseases.

  2015influential citation
• Correlation Between the CYP2C19 Phenotype Status and the Results of Three Different Platelet Function Tests in Cardiovascular Disease Patients Receiving Antiplatelet Therapy: An Emphasis on Newly Introduced Platelet Function Analyzer-200 P2Y Test

  2015cites this paper
• Effect of common single nucleotide polymorphisms in COX-1 gene on related metabolic activity in diabetic patients treated with acetylsalicylic acid

  2013cites this paper